All In Biotech

Drug Trial Radar · NCT03742102

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 243 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

243

Actual

Start

Dec 21, 2018

Primary completion

Nov 29, 2024

Study completion Feb 26, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Conditions

  • Triple Negative Breast Neoplasms

Interventions

  • DurvalumabDrug

    Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

  • CapivasertibDrug

    Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off

  • OleclumabDrug

    Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1

  • PaclitaxelDrug

    Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

  • Trastuzumab deruxtecanDrug

    Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w

  • Datopotamab deruxtecanDrug

    Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT) EventsTime frame: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))

Locations

32 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona

  • Research Site

    Columbia, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Dallas, Texas

  • Research Site

    Williamsburg, Virginia

  • Research Site

    Kelowna, British Columbia, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Greenfield Park, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Gdansk, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Lublin, Poland

  • Research Site

    Opole, Poland

  • Research Site

    Rzeszów, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taoyuan, Taiwan

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.